ONCOLOGY

Biopsy needed to select patients for salvage treatment.

AQUARIUS shows advantage in terms of fatigue and cognitive function.

But be cautious: longer follow-up is needed to assess the freedom from distant metastases at ten years

Cabazitaxel superior to abiraterone, enzalutamide as a third-line treatment.

“Practice-changing” study is first success with targeted therapy in this setting.

Targeted and immunotherapy for GI and GU tumours.

Meta-analysis combines evidence from three trials.

Study suggests early prostate cancer screening and long-term monitoring should be considered for these men.

IMPACT study points to need for regular PSA screenings.

Phase 3 trial shows no increase in acute toxicity.

Phase 3 trial shows survival benefit in metastatic castration-sensitive disease.

Data from 376 men carrying BRCA1 mutations and 447 carrying BRCA2 mutations.

Meta-analysis of 8 multinational phase 3 prostate cancer clinical trials.

Findings combined with PSA density can stratify risk for future upgrading.